Antibody Information
General Information of This Antibody
| Antibody ID | ANI0TEFTG |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | BCMA-Ab1 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG |
|||||
| Antigen Name | Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
MEDI2228 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must be ≥18 years with relapsed/refractory multiple myeloma (IMWG criteria) who exhausted standard therapies, have measurable disease, ECOG 0-1, and adequate organ function. Exclusions include recent stem cell transplants (<90 days), CNS involvement, plasma cell disorders, or conditions interfering with safety assessments.
|
||||
| Administration Dosage |
Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with relapsed/refractory (R/R) multiple myeloma (MM).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03489525 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
|
||||
| Primary Endpoint |
The study evaluates safety through monitoring adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) from informed consent through 90 days post-treatment, including laboratory tests, vital signs, and ECG changes assessed up to 21 days after treatment completion.
|
||||
| Other Endpoint |
Pharmacokinetic analysis measures MEDI2228 concentration, clearance, and half-life over 60 days post-treatment while assessing immunogenicity via anti-drug antibodies. Efficacy endpoints including objective response rate, clinical benefit rate, duration of response, progression-free survival, and overall survival are evaluated for up to three years post-enrollment.
Click to Show/Hide
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
61%
|
|||
| Patients Enrolled |
Eligible pts were 18 years old with confirmed relapsed/refractory multiple myeloma (R/R MM) as defined by International Myeloma Working Group consensus criteria, had measurable disease, and had an Eastern Cooperative Oncology Group performance status 1. Pts had to have progressed after treatment with three classes of standard-of-care anti-myeloma drugs, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies (mAbs).
Click to Show/Hide
|
||||
| Administration Dosage |
Administered in the dose of 0.0125-0.20 mg/kg intravenously every 3 weeks (Q3W); The maximum tolerated dose was 0.14 mg/kg Q3W.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03489525 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1, open-label study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of MEDI2228 in subjects with relapsed/refractory multiple myeloma.
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 82.05% | |||
| Method Description |
The inhibitory activity of MEDI-2228 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.3 mg/kg MEDI-2228.
|
||||
| In Vivo Model | NSG mice model | ||||
| In Vitro Model | Plasma cell myeloma | MM1.S cells | CVCL_8792 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.46% | |||
| Method Description |
The inhibitory activity of MEDI-2228+NK against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.3 mg/kg MEDI-2228.
|
||||
| In Vivo Model | NSG mice model | ||||
| In Vitro Model | Plasma cell myeloma | MM1.S cells | CVCL_8792 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.94% | |||
| Method Description |
The inhibitory activity of MEDI-2228+NK+Dara against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.3 mg/kg MEDI-2228.
|
||||
| In Vivo Model | NSG mice model | ||||
| In Vitro Model | Plasma cell myeloma | MM1.S cells | CVCL_8792 | ||
Obtained from the Model Organism Data
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 67.99% | |||
| Method Description |
The inhibitory activity of MEDI-2228 against cancer cell growth was evaluated in various human cancer cell lines in vivo.The cells were treated with 0.4 mg/kg MEDI-2228.
|
||||
| In Vivo Model | CB17 SCID mice model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.12% | |||
| Method Description |
The inhibitory activity combination of M2 and btz for 2 weeks against cancer cell growth was evaluated in various human cancer cell lines in vivo.
|
||||
| In Vivo Model | CB17 SCID mice model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Effective Dose (EC50) |
189.7 ng/mL
|
|||
| Method Description |
The inhibitory activity of MEDI-2228 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Plasma cell myeloma | RPMI-8226 cells | CVCL_0014 | ||
References